Drug intelligence / Profile preview

vax161

Development stage: Phase 1
Lead developer: VaxInnate
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VAX161 is a recombinant fusion protein vaccine developed for the prevention of pandemic avian influenza (bird flu) caused by the influenza A virus subtype H5N1. It consists of the globular head domain of the hemagglutinin antigen (HA) from influenza A HA5 Indonesia fused to Salmonella typhimurium flagellin type 2 (STF2), which acts as a toll-like receptor 5 ligand. The vaccine is administered via intramuscular injection and was designed to induce an immune response against highly pathogenic avian influenza viruses[2][3][1].

Other names: VAX161C vaccineVAX-161C vaccineVAX 161C vaccineRecombinant H5 influenza vaccine

Targets

TLR5HA head (Hemagglutinin globular head domain)

Beyond the preview

Go deeper on vax161.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vax161.

Explore the full profile